TriangleNCT00085735 · OUTCOME
Non-local Posterior Fossa (NLPF) Failure Rate
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Percentage of 3 yr cumulative incidence
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- 3 years
What was measured
NLPF failure was defined as tumor recurrence/progression outside the radiation therapy clinical target volume boost (CTV-boost) but within the posterior fossa CTV (CTV-PF). The cumulative incidence (CI) of NLPF failure was estimated; 3-year estimates were reported with 95% confidence intervals. Patients with other failure types (e.g., NPF, LPF) and with other events prior to NLPF failure (e.g., death, second malignancy) were considered as having competing events.
Analysis population: Eligible and evaluable patients 3-21 yrs of age are included. Patients with anaplastic histology or disseminated/excess residual disease were not evaluable (NE). Arms I/III/V \[IFRT\] are combined \& arms II/IV/VI \[PFRT\] are combined. 26 \& 23 IFRT \& PFRT pts were NE and were excluded, leaving 227 and 237 eligible and evaluable pts.
Groups in this outcome
Involved Field Radiation (IFRT)
Includes eligible patients 3-21 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and randomized to one of the IFRT arms (Treatment Arms I, III, V)
Posterior Fossa Radiation (PFRT)
Includes eligible patients 3-21 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and randomized to one of the PFRT arms (Treatment Arms II, IV, VI).
| Group | Source count |
|---|---|
| Involved Field Radiation (IFRT) | 227 |
| Posterior Fossa Radiation (PFRT) | 237 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Involved Field Radiation (IFRT) | 6.9 | Not reported | 3.5 | 10.3 | Not reported |
| Posterior Fossa Radiation (PFRT) | 2.7 | Not reported | 0.6 | 4.8 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 3.5
- upper Limit
- 10.3
- value
- 6.9
- group Id
- OG001
- lower Limit
- 0.6
- upper Limit
- 4.8
- value
- 2.7
- denoms
- counts
- group Id
- OG000
- value
- 227
- group Id
- OG001
- value
- 237
- units
- Participants
- description
- NLPF failure was defined as tumor recurrence/progression outside the radiation therapy clinical target volume boost (CTV-boost) but within the posterior fossa CTV (CTV-PF). The cumulative incidence (CI) of NLPF failure was estimated; 3-year estimates were reported with 95% confidence intervals. Patients with other failure types (e.g., NPF, LPF) and with other events prior to NLPF failure (e.g., death, second malignancy) were considered as having competing events.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Includes eligible patients 3-21 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and randomized to one of the IFRT arms (Treatment Arms I, III, V)
- id
- OG000
- title
- Involved Field Radiation (IFRT)
- description
- Includes eligible patients 3-21 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and randomized to one of the PFRT arms (Treatment Arms II, IV, VI).
- id
- OG001
- title
- Posterior Fossa Radiation (PFRT)
- param Type
- NUMBER
- population Description
- Eligible and evaluable patients 3-21 yrs of age are included. Patients with anaplastic histology or disseminated/excess residual disease were not evaluable (NE). Arms I/III/V \[IFRT\] are combined \& arms II/IV/VI \[PFRT\] are combined. 26 \& 23 IFRT \& PFRT pts were NE and were excluded, leaving 227 and 237 eligible and evaluable pts.
- reporting Status
- POSTED
- time Frame
- 3 years
- title
- Non-local Posterior Fossa (NLPF) Failure Rate
- type
- SECONDARY
- unit Of Measure
- Percentage of 3 yr cumulative incidence
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice